Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kamran Ahmed
Moffitt Cancer Center
Principal Investigator - Matthew Mills
Moffitt Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moffitt Cancer Center
Tampa, Florida, United States
Aixa Soyano Muller, MDAvan Armaghani, MDHatem Soliman, MDIman Washington, MDKamran Ahmed, MDLoretta Loftus, MDMatthew Mills, MDRicardo Costa, MDRoberto Diaz, MD, PhDTracey O'Connor, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Feb 2025
- Primary completion
- 31 Oct 2026
- Completion
- 31 Oct 2026
- Last update posted
- 2 Jul 2026
- Registered enrollment
- 120
- Registry id
- NCT06833502
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.